SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

Attention centers on CRISPR Therapeutics CTX310 clinical data and other pipeline readouts, with traders debating whether encouraging results can shift sentiment toward its in-vivo gene-editing and autoimmune programs. Optimism about the catalysts and Casgevys commercial ramp is tempered by frustration that the stock has remained range-bound and may not respond to positive developments.

Starbucks Corp. engages in the production, marketing, and retailing of specialty coffee. It operates through the following segments: North America, International, and Channel Development. The North America segment focuses on the United States and Canada. The International segment is involved in China, Japan, Asia Pacific, Europe, Middle East, Africa, Latin America, and Caribbean. The Channel Development segment includes roasted whole bean and ground coffees, Seattle’s Best Coffee, and Teavana-branded single-serve products. The company was founded by Jerry Baldwin and Howard D. Schultz on November 4, 1985, and is headquartered in Seattle, WA.

Starbucks Corp.

Starbucks Corp

Starbucks quarterly results sparked debate after stronger-than-expected earnings and comparable sales were offset by a revenue miss, with the China restructuring weighing on reported sales and the stocks reaction remaining subdued. Bulls point to improving U.S. traffic and the turnaround outlook, while bears question the valuation and whether growth can justify it.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCath reimbursement could decline sharply through 2027 has weighed on CRMD, intensifying concerns about pricing and revenue from its flagship product. Traders disagree on how decisive the warning is: some view DaVitas estimates as preliminary and point to CMS reimbursement and adoption as offsets, while others see lasting pressure on the business outlook.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Takeover speculation has fueled attention after reports that Lundbeck explored acquiring Xeris, though the company said it is not for sale and traders disagree on whether a deal is likely. The discussion also centers on upcoming quarterly results and the longer-term potential of Recorlev growth and XP-8121s planned Phase 3 program.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Ciscos decline is being tied to an analyst price-target cut amid concerns that networking growth may be peaking and the stocks valuation could compress; the firm kept its rating unchanged. Traders are split between calling the selloff an overreaction given AI-networking demand and seeing continued technical weakness.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Traders are split on Disneys choppy, range-bound trading, with bullish breakout and call-positioning talk countered by bearish bets on a pullback. Some posts also react negatively to allegations involving the company, but the discussion does not establish them as a confirmed market catalyst.

BNB (BNB) is a cryptocurrency . BNB has a current supply of 131,511,387.69. The last known price of BNB is 703.59425696 USD and is up 0.47 over the last 24 hours. It is currently trading on 3523 active market(s) with $2,735,089,335.64 traded over the last 24 hours. More information can be found at https://bnbchain.org/en.

Binance

A reported multibillion-dollar Binance security breach is driving attention, with traders focused on suspended withdrawals and concerns about exchange security and customer funds. The community debates whether Binance can cover the losses and whether BNBs limited decline understates the risk; claims of an inside job or specific perpetrators remain speculation.

Invesco Exchange-Traded Fund Trust - Invesco S&P 500 Equal Weight ETF

Invesco S&P 500 Equal Weight ETF

RSP is drawing attention as a gauge of market breadth and the rotation between mega-cap tech and the broader S&P 500: traders have highlighted periods of equal-weight outperformance as participation widens beyond AI and tech leaders. The reaction is mixed, with some viewing the rotation as healthy broadening and others warning that recent RSP weakness signals deteriorating breadth and renewed concentration in a few large stocks.

Pudgy Penguins (PENGU) is a cryptocurrency launched in 2024and operates on the Solana platform. Pudgy Penguins has a current supply of 76,724,221,264.3 with 62,860,396,090.04 in circulation. The last known price of Pudgy Penguins is 0.00754361 USD and is up 6.59 over the last 24 hours. It is currently trading on 540 active market(s) with $130,377,930.32 traded over the last 24 hours. More information can be found at https://www.pengu.pudgypenguins.com.

Pudgy Penguins

PENGU is drawing attention around its pullback and attempts to hold a technical support zone, with traders debating whether it can rebound or break lower. Dip buyers point to possible support and broader crypto-market recovery, while bears cite persistent selling, weak momentum and a lack of fresh catalysts.

Barrick Mining Corp. engages in the production and sale of gold, copper, and related activities. It also provides exploration and mining development. It operates through the following business segments: Carlin, Cortez, Turquoise Ridge, Pueblo Viejo, Loulo-Gounkoto, Kibali, Veladero, North Mara, Bulyanhulu, and Other Mines. The company was founded by Peter D. Munk in 1983 and is headquartered in Toronto, Canada.

Barrick Mining Corp.

Barrick Mining Corp

Barrick is drawing attention as its shares and the wider mining sector face pressure, with repeated technical analysis suggesting the correction may not be over. Traders are divided between expecting further weakness and treating the pullback as an opportunity to add, while gold-price and interest-rate concerns weigh on near-term sentiment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

12 Health Care Stocks Moving In Tuesday's After-Market Session

Gainers

Neumora Therapeutics (NASDAQ:NMRA) shares rose 11.9% to $0.41 during Tuesday's after-market session. The market value of their outstanding shares is at $73.8 million.
Pulmonx (NASDAQ:LUNG) stock increasedread more...

NMRA Investor Alert: Levi & Korsinsky Investigates Neumora Therapeutics (NMRA) for Potential Securities Fraud

Neumora Therapeutics (NASDAQ: NMRA) shareholders watched their investment collapse today after the company disclosed that navacaprant failed both Phase 3 KOASTAL-2 and KOASTAL-3 trials in major depressive disorder and announced an immediate workforce reduction of approximately 35%. Investors who...

NMRA SHAREHOLDER INVESTIGATION: SueWallSt Investigates Neumora Therapeutics for Possible Securities Law Violations

NMRA SHAREHOLDER INVESTIGATION: SueWallSt Investigates Neumora Therapeutics for Possible Securities Law Violations NMRA SHAREHOLDER INVESTIGATION: SueWallSt Investigates Neumora Therapeutics for Possible Securities Law Violations PR Newswire NEW YORK, June 17, 2026 Neumora Therapeutics...

Neumora Therapeutics Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Neumora Therapeutics (NMRA)

Neumora Therapeutics Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Neumora Therapeutics (NMRA) Neumora Therapeutics Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Neumora Therapeutics (NMRA) PR Newswire NEW YORK, June 16...

Neumora Stock Plunges 49% After Late-Stage Depression Drug Failure

NMRA stock sinks 49% after phase III depression studies show navacaprant's failure to meet key goals, leading to discontinuation of its development.

NMRA Stock On Track For Worst Day In 1.5 Years — Neumora Therapeutics' Lead Depression Drug Fails Late Stage Trials

Equity

The company described the results as disappointing and added that it is immediately discontinuing development of navacaprant.


Neumora Therapeutics (NMRA) Projected to Post Quarterly Earnings on Monday

Neumora Therapeutics (NASDAQ:NMRA) will be releasing its Q1 2026 earnings after the market closes on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-neumora-therapeutics-inc-stock...

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Rating of "Moderate Buy" by Analysts

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the nine brokerages that are covering the firm, Marketbeat reports...

Q2 EPS Forecast for Neumora Therapeutics Boosted by Analyst

Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) - Equities researchers at HC Wainwright increased their Q2 2026 earnings per share (EPS) estimates for shares of Neumora Therapeutics in a...

Guggenheim Reaffirms "Buy" Rating for Neumora Therapeutics (NASDAQ:NMRA)

Guggenheim reiterated a "buy" rating and issued a $14.00 target price on shares of Neumora Therapeutics in a report on Tuesday...

Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. The firm offers a precision medicine approach for brain diseases through the integration of data science and neuroscience. It focuses on advancing medicines for therapeutically relevant targets implicated in CNS diseases, targeting novel mechanisms of action with best-in-class pharmacology. The company was founded by Paul L. Berns, Carol Suh and Mike Poole in November 2019 and is headquartered in Watertown, MA.

Neumora Therapeutics Inc.

Bearish Sentiment

<ul class="summary-bullets"><li>To conserve cash and refocus resources, Neumora Therapeutics now plans to cut its workforce by about 35%.&nbsp;</li><li>Navacaprant had served as Neumora Therapeutics’ most advanced program.&nbsp;</li><li>Chief Executive Paul Berns said the firm remains “excited about the best-in-class potential” of the updated portfolio despite the setback on its former lead program.</li></ul> Shares of Neumora Therapeutics (NMRA) plunged nearly 47% after the company said that its lead drug candidate, navacaprant, did not outperform placebo in treating major depressive disorder in two late-stage trials.The stock is now on track to clock its worst day since January 2025, if losses hold.<h2 class="st-heading-2">NMRA’s Disappointment Trails</h2>In the KOASTAL-2 and KOASTAL-3 studies, which together enrolled more than 850 adults, patients taking the drug showed similar or slightly smaller improvements in depression symptoms after six weeks compared with those on placebo. Neither trial met its main goal of demonstrating a statistically meaningful benefit.The company described the results as disappointing and added that it is immediately discontinuing development of navacaprant. Navacaprant had served as Neumora Therapeutics’ lead and most advanced program.<h2 class="st-heading-2">Neumora’s Next Steps</h2>To conserve cash and refocus resources, Neumora now plans to cut its workforce by about 35%, generating roughly $10 million in annual savings after one-time costs. It said existing cash provides a runway into the third quarter of 2027.The company highlighted progress in its remaining pipeline, including NMRA-511 for agitation in Alzheimer’s disease, NMRA-898 for schizophrenia, and NMRA-215 for cardiometabolic conditions. It expects multiple clinical data readouts and study starts over the next 12 months.Chief Executive Paul Berns said the firm remains “excited about the best-in-class potential” of the updated portfolio despite the setback on its former lead program.<h2 class="st-heading-2">How Did NMRA Retail Traders React?</h2>On Stocktwits, retail sentiment around NMRA stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.According to data from Koyfin, seven of the nine analysts covering NMRA rate it ‘Buy’ or higher, while one rates to ‘Hold’ and one ‘Strong Sell.’ The 12-month average price target on the stock is $8.91, representing a potential upside of over 400% from the stock’s last closing price.A Stocktwits user expressed optimism in the company’s remaining pipeline.<stembedurl>https://www.stocktwits.com/Mr_GA/message/656452972</stembedurl>Yet another user opined that the company is “not dead yet.”<stembedurl>https://www.stocktwits.com/Mr_GA/message/656452972</stembedurl>A third user expressed hopes for the company’s experimental drug for obesity, which is slated to enter clinical trials by the end of the year.<stembedurl>https://www.stocktwits.com/Buying_Low_Selling_High/message/656455396</stembedurl><a href="https://stocktwits.com/symbol/NMRA">NMRA stock</a> has lost about 42% this year.&nbsp;Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/spcx-stock-rises-spacex-underwriters-exercise-option/cZKf8h4R73K">SPCX Stock Extends Its Relentless Rally – SpaceX Expands Historic IPO To $85.7B After Underwriters Exercise Greenshoe Option</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In the wake of OWL's redemption restrictions, Senator Elizabeth Warren called for tighter oversight of private credit.

The company described the results as disappointing and added that it is immediately discontinuing development of navacaprant.

Vanguard Total Stock Market ETF

Vanguard Extended Market ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$0.3672
Prev Close	$0.3883
Open	$0.4068
Dividend Yield	0.00%
50-Day Moving Average	$0.7925
Beta	1.46
Avg. Volume	1.7M
PE Ratio	-0.30

52-Week High	$3.65
52-Week Low	$0.3154
Market Capitalization	$69M
EPS (Annual)	-$1.45
Price to Book	1.54
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

NMRA Fundamentals